Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $246.89 +3.06%
Revenue Growth %: +15.3%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +15.3%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.08 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $125.9 million versus the consensus estimate of $120.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- HP Inc. projects mid-single-digit PC market decline in 2027
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
